Galera announces receipt of type a meeting minutes and strategic update

Fda confirms need for new trial for avasopasem for severe oral mucositis (som) greco-2 trial did not pass futility analysis; company will discontinue both greco trials company reviewing potential strategic alternatives to maximize shareholder value malvern, pa., oct. 31, 2023 (globe newswire) -- galera therapeutics, inc. (nasdaq: grtx), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that it has received official meeting minutes from the type a meeting with the united states food and drug administration (fda) held september 28, 2023 in which the fda reiterated the need for an additional phase 3 trial of avasopasem manganese (avasopasem) for radiotherapy-induced som.
GRTX Ratings Summary
GRTX Quant Ranking